2009 Leadership in innovation
Award
Winner and Keynoter
Patrick Soon-Shiong, MD
Chairman & CEO of Abraxis Health
Patrick Soon-Shiong is Executive
Chairman and CEO of
Abraxis Health,
which is forging a new paradigm for
the delivery of healthcare,
requiring a novel global
infrastructure, integrating
bioinformatics, discovery, molecular
medicine and clinical development.
Under this model, Abraxis Health
will develop, test and validate
diagnostics and drugs to target
pre-selected patients based on
molecular profiles that predict drug
response to particular therapeutics.
This will enable the delivery of
drugs to patients in a predictive,
preventative and evidence-based
manner, improving outcomes and
pharmacoeconomics.
A noted researcher, physician and
surgeon,
Patrick is a co-inventor of over 50
issued U.S. patents, has published
more than 100 scientific papers, and
founded two publicly traded
pharmaceutical companies, American
Pharma Partners and Abraxis
Bioscience,
a fully integrated global
biotechnology company dedicated to
the discovery, development and
delivery of next-generation
therapeutics and core technologies
that offer patients safer and more
effective treatments for cancer and
other critical illnesses.
Pat served as Chairman and CEO of
Abraxis Bioscience until April 2009.
There,
he developed and co-invented
the nanoparticle delivery technology
known as Abraxane, which is used in
the treatment of advanced metastatic
breast cancer. Abraxane
was launched in 2005 and is now
approved in 36 countries.
This technology is also being
developed for lung, ovarian,
prostate, melanoma, head and neck
cancers.
In September 2008, Abraxis
Bioscience sold its division called
APP Pharmaceuticals to Fresenius SE
for approximately $3.7 billion. In
2009, Patrick launched Abraxis
Health and
formed the Chan Soon-Shiong Family
Foundation, through which he and his
family are focusing on charitable
endeavors that will improve
healthcare in America and the
welfare of its patients. Patrick's
vision is to transform healthcare
from a qualitative practice of
medicine to a quantitative,
personalized, predictive, preventive
and evidence-based medicine at the
point of care at the time of need.
Patrick is on the health advisory
board and the President's Council of
RAND, where he supported the
development of the Comprehensive
Assessment of Reform Efforts
(COMPARE), recently released by the
RAND Corporation.
Also in 2009, he was appointed
Chairman of the Steering Committee
of Life Sciences of the X-Prize
Foundation, Board Member of ITA
partners, Founding Board Member to
Dossia Foundation, Executive
Director of the UCLA Wireless Health
Institute, and is Professor of
Microbiology, Immunology, and
Molecular Genetics Professor of
Bioengineering at UCLA. In 2008,
Patrick received the Medical
Visionary Award from the Pancreatic
Cancer Action Network. Also notable
in his career, Patrick performed the
world’s first encapsulated islet
transplant in a diabetic patient.
2008
Leadership In Innovation Award
Winner and Keynote
Steve Case
Chairman & CEO of Revolution
Health Group
Steve will address the audience
on how putting the "consumer" in
the center of healthcare can
revolutionize the industry.
Steve feels the healthcare
system doesn't need incremental
"band-aid" type approaches.
It needs fresh thinking.
It needs a revolution, led by
the people, for people.
That's what Steve is hoping to
catalyze at Revolution Health,
and what we'll hear about.
read more
